🔍

Choksi Laboratories Ltd (526546)

📊 BSE: 526546 🏢 Healthcare Service Provider 📢 Latest filing: 24 Sep 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Choksi Laboratories' revenue was ₹12.1 Cr (+7.5% year on year, -5.8% on the previous quarter), and net profit ₹0.6 Cr (+49.3% year on year); the operating margin was 27.3%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹12.1	+7.5%	-5.8%
Operating profit	₹3.3	+13.8%	-9.3%
Net profit	₹0.6	+49.3%	-43.5%
EPS (₹)	0.84	+50.0%	-43.2%
Operating margin	27.3%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Choksi Laboratories Calls EGM to Issue ₹6.20 Cr Convertible Warrants to Promoters at ₹177/Share

🟢 POSITIVE ⭐ 6/10

FUNDRAISE 📅 24 Sep 2026, 05:32 PM

Choksi Laboratories has convened an Extra-Ordinary General Meeting (EGM) on October 17, 2026, to approve the preferential issuance of up to 3,50,000 convertible warrants at ₹177 each to promoters, raising up to ₹6,19,50,000. The proposed issuance represents approximately 4.2% of the company's current ₹146 Cr market cap. Upon full conversion within 18 months, promoter shareholding will increase from 31.48% (21,92,754 shares) to 34.76% (25,42,754 shares). The warrant issue price of ₹177 is at a discount to the current market price of ₹209.9.

Preferential allotment of up to 3,50,000 convertible warrants at an issue price of ₹177 per warrant (including ₹167 premium)
Aggregate fundraise of up to ₹6,19,50,000 (~₹6.20 Cr) for cash consideration
Promoter holding to increase from 31.48% to 34.76% on fully diluted equity share capital post-conversion
E-voting runs from October 14 to October 16, 2026, with the EGM scheduled for October 17, 2026

💡 Track shareholder voting results on or before October 19, 2026, and in-principle approval from BSE. Monitor subsequent warrant subscription and deployment of proceeds toward business operations or debt reduction.

Choksi Laboratories approves ₹6.20 Cr preferential warrant issue to promoters at ₹177/share

🟢 POSITIVE ⭐ 6/10

FUNDRAISE 📅 19 Sep 2026, 05:59 PM

Choksi Laboratories' board has approved the issuance of up to 3,50,000 convertible equity warrants on a preferential basis to promoters at an issue price of ₹177 per warrant, aggregating to ₹6.20 crore. The fundraise equals ~4.2% of the company's current market cap of ₹146 crore and will inject fresh equity into the balance sheet. An upfront payment of 25% is payable on subscription, with the remaining 75% payable on conversion within 18 months. The issuance is subject to shareholder approval at an Extra-Ordinary General Meeting scheduled for October 17, 2026.

Board approved issuance of up to 3,50,000 convertible warrants at ₹177 per warrant, raising up to ₹6,19,50,000
Allotment is entirely to 3 promoter individuals: Sunil Choksi (2,00,000 warrants), Himika Choksi (1,00,000), and Stela Choksi (50,000)
Payment structured as 25% on subscription and allotment, with balance 75% upon conversion within an 18-month tenure
EGM to approve the preferential issue scheduled for October 17, 2026

💡 Track voting outcomes at the upcoming EGM on October 17, 2026, and monitor the end-use of proceeds once disclosed (e.g. debt repayment or capex).

Choksi Laboratories Intimates Dispatch of 33rd AGM Notice and FY26 Annual Report Weblink

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 27 Aug 2026, 12:51 PM

Choksi Laboratories Limited has issued an intimation under Regulation 36(1)(b) of SEBI LODR regarding the dispatch of letters to shareholders whose email addresses are not registered. The communication provides access links to the 33rd Annual Report for FY 2025-26 and the AGM Notice. The 33rd Annual General Meeting is scheduled to be held on Friday, September 18, 2026, at 12:30 p.m. via Video Conferencing.

33rd Annual General Meeting scheduled for September 18, 2026, at 12:30 p.m. via Video Conferencing
Communication sent to shareholders without registered email IDs to access the FY 2025-26 Annual Report
Letters dispatched in compliance with Regulation 36(1)(b) of SEBI LODR Regulations
RTA Ankit Consultancy Private Limited listed for updating shareholder contact details

💡 Shareholders should review the 33rd Annual Report and participate in the AGM voting scheduled for September 18, 2026.

Choksi Laboratories Submits FY26 Annual Report; 33rd AGM Scheduled on Sep 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Aug 2026, 07:04 PM

Choksi Laboratories Limited has released its 33rd Annual Report for FY2025-26 and scheduled its Annual General Meeting (AGM) for September 18, 2026. Key agenda items include the re-appointment of Ms. Himika Choksi as Whole-time Director for a five-year term starting April 1, 2027. Disclosures highlight FY26 ROCE at 13.85% (up from 12.37%) and Debt-Equity at 1.34x (vs 1.24x). The report also notes a past ransomware breach on May 22, 2025, resolved with data fully recovered at a cost of ₹2.60 Lakhs.

33rd Annual General Meeting scheduled for Friday, September 18, 2026, via Video Conferencing.
Proposed re-appointment of Ms. Himika Choksi as Whole-time Director for 5 years effective April 1, 2027.
FY26 Debt-to-Equity ratio stood at 1.34x compared to 1.24x in the previous year.
FY26 Return on Capital Employed (ROCE) improved to 13.85% from 12.37% in FY25.
Data recovered from a May 22, 2025 ransomware incident at a remediation cost of ₹2.60 Lakhs.

💡 Track voting outcomes at the upcoming AGM on September 18, 2026, and monitor working capital and leverage metrics in upcoming quarterly earnings.

Choksi Laboratories Convenes 33rd AGM on September 18, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Aug 2026, 06:57 PM

Choksi Laboratories Limited has submitted the notice convening its 33rd Annual General Meeting (AGM) scheduled for Friday, September 18, 2026, at 12:30 PM IST via Video Conference / Other Audio-Visual Means. The company has also released its Annual Report for the financial year ended March 31, 2026 (FY26), during which it generated revenue of ₹46.01 crore and net profit of ₹1.96 crore. The filing is a standard regulatory compliance requirement pursuant to SEBI Listing Regulations.

33rd Annual General Meeting scheduled for September 18, 2026, at 12:30 PM IST
Meeting to be conducted virtually through Video Conference / Other Audio-Visual Means
Annual Report for FY26 dispatched electronically to registered shareholders
Company reported FY26 revenue of ₹46.01 crore and PAT of ₹1.96 crore

💡 Shareholders may review the FY26 Annual Report for management commentary on business segments and participate in voting on AGM agenda resolutions.

Choksi Labs Receives 4 USFDA Observations for Indore Central Laboratory

🔵 WATCH ⭐ 7/10

REGULATORY 📅 21 Aug 2026, 05:09 PM

The USFDA conducted an inspection of Choksi Laboratories' central laboratory in Indore from August 17 to August 20, 2026. Upon conclusion of the inspection, the agency issued 4 observations to the company. Choksi Laboratories stated it is addressing the observations comprehensively and will submit its response within the stipulated timeframe.

USFDA inspection conducted at Indore central laboratory between August 17, 2026, and August 20, 2026
Company received 4 observations at the conclusion of the inspection
Company committed to responding to the USFDA within the stipulated timeframe
Pertains to core testing infrastructure for a company with TTM revenue of Rs 47 Cr

💡 Track the company's response submission within the 15-day regulatory window and subsequent USFDA classification (e.g., NAI, VAI, or OAI) or EIR issuance.

Choksi Laboratories Re-appoints M/s Tanmay V. Rajurkar & Co. as Internal Auditor for FY 2026-27

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 13 Aug 2026, 05:28 PM

Choksi Laboratories has re-appointed M/s Tanmay V. Rajurkar & Co. as its Internal Auditor for the financial year 2026-27. This is a routine compliance-driven move under the Companies Act, 2013 and SEBI LODR regulations. The firm (FRN: 012166C) will oversee internal controls for the company, which currently has a market capitalization of Rs 81 Cr and TTM revenue of Rs 47 Cr. The appointment ensures continuity in financial oversight and regulatory adherence.

Re-appointment of M/s Tanmay V. Rajurkar & Co. (FRN: 012166C) as Internal Auditor.
Appointment effective from August 13, 2026, for the Financial Year 2026-27.
Company maintains a TTM Operating Profit Margin (OPM) of 26.8% on Rs 47 Cr revenue.
The firm specializes in corporate taxation, audit, and legal matters.

💡 This is a routine administrative filing. Investors should focus on the company's ability to manage its high debt-to-equity ratio of 1.20 and upcoming quarterly earnings performance.

5-Year Re-appointment of Ms. Himika Choksi as Whole Time Director at Choksi Laboratories

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 13 Aug 2026, 05:22 PM

Choksi Laboratories has approved the re-appointment of Ms. Himika Choksi as Whole Time Director for a five-year term starting April 1, 2027. Ms. Choksi is a promoter member with 25 years of experience in Quality Assurance and Control. She is a relative of the Managing Director and other board members, maintaining the company's family-led management structure. The appointment is subject to shareholder approval at the upcoming Annual General Meeting for the company, which currently has a market capitalization of Rs 81 crore.

Re-appointment for a 5-year term effective from April 1, 2027, to March 31, 2032.
Ms. Himika Choksi possesses 25 years of experience in Quality Assurance and Control.
The appointee is a promoter member and daughter of the Managing Director, Mr. Sunil Choksi.
Company maintains a TTM revenue of Rs 47 crore with an Operating Profit Margin of 26.8%.
Promoter holding remains stable at 31.48% as of June 2026.

💡 Investors should monitor the upcoming Annual General Meeting for shareholder approval of this re-appointment and check for any significant changes in executive remuneration.

Choksi Laboratories Approves Q1 FY27 Results; Auditor Issues Clean Review Report

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 13 Aug 2026, 03:27 PM

Choksi Laboratories approved its unaudited financial results for the quarter ended June 30, 2026, on August 13, 2026. The statutory auditor, Prateek Jain & Co., issued a clean limited review report, confirming no material misstatements in the interim financials. The company, a micro-cap with a market capitalization of Rs 83 Cr, maintains a TTM revenue of Rs 46 Cr. Investors should note the company's debt levels, which at Rs 31 Cr, result in a debt-to-equity ratio of 1.20.

Board approved unaudited financial results for the quarter ended 30th June, 2026
Auditor Prateek Jain & Co. (FRN: 009494C) issued a clean Limited Review Report on 13th August, 2026
Company operates with a TTM revenue of Rs 46 Cr and a TTM PAT of Rs 2 Cr
Debt of Rs 31 Cr currently exceeds the company's net worth of Rs 26 Cr
Promoter holding remained stable at 31.48% as of the June 2026 quarter

💡 Monitor the detailed P&L statement for revenue growth trends relative to the Rs 11.24 Cr reported in the same quarter last year and check for any improvement in the 26.4% operating margin.

Choksi Laboratories Approves Q1 FY27 Results and Re-appoints Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 13 Aug 2026, 03:22 PM

Choksi Laboratories held its board meeting on August 13, 2026, approving the unaudited financial results for the quarter ended June 30, 2026. The company scheduled its 33rd Annual General Meeting (AGM) for September 18, 2026, and set the book closure period from September 12 to September 18, 2026. A key leadership decision included the re-appointment of Ms. Himika Choksi as Whole Time Director for a five-year term effective April 1, 2027. Additionally, the company transitioned its Registrar and Share Transfer Agent (RTA) to Ankit Consultancy Private Limited.

Approved unaudited financial results for the quarter ended June 30, 2026
Re-appointed Ms. Himika Choksi as Whole Time Director for a 5-year term starting April 1, 2027
Scheduled the 33rd Annual General Meeting for September 18, 2026, via video conferencing
Changed Registrar and Share Transfer Agent from MUFG Intime India to Ankit Consultancy Private Limited
Set the share transfer book closure period from September 12 to September 18, 2026

💡 Investors should monitor the detailed Q1 FY27 financial tables (to be filed separately) to see if the company maintains its 26.4% operating margin against the TTM revenue of Rs 46 Cr.

Aug 13 Board Meeting to Approve Q1 FY27 Results and Appoint Internal Auditor

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 05 Aug 2026, 05:51 PM

Choksi Laboratories has scheduled a board meeting for August 13, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The board will also consider the appointment of an Internal Auditor for the 2026-27 fiscal year and discuss matters related to the upcoming Annual General Meeting. This follows a fiscal year (FY26) where the company reported a revenue of Rs 46.01 Cr and a net profit of Rs 1.96 Cr. The meeting is a routine regulatory requirement under SEBI LODR regulations.

Board meeting scheduled for August 13, 2026, at 02:30 P.M. at the Indore registered office.
Agenda includes approval of unaudited financial results for the quarter ended June 30, 2026.
Board to consider the appointment of an Internal Auditor for the financial year 2026-27.
Trading window for designated persons has been closed since July 1, 2026, and will reopen 48 hours after result declaration.

💡 Monitor the Q1 FY27 results on August 13 to see if the company can improve upon the Rs 1.03 Cr PAT reported in the previous quarter (March 2026).

Choksi Laboratories Changes Registrar and Share Transfer Agent to Ankit Consultancy

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Aug 2026, 05:14 PM

Choksi Laboratories has transitioned its Registrar and Share Transfer Agent (RTA) from MUFG Intime India Private Limited to Ankit Consultancy Private Limited, effective August 03, 2026. The change applies to electronic connectivity with both NSDL and CDSL. The company cited service offerings, technological capabilities, and local convenience as the primary reasons for the shift. This is a procedural administrative update and does not impact the company's financial performance or core operations.

RTA change effective from August 03, 2026
New RTA: Ankit Consultancy Private Limited (SEBI Reg No. INR000000767)
Previous RTA: MUFG Intime India Private Limited (SEBI Reg No. INR000004058)
Tripartite agreement between the company and both RTAs to be executed in due course

💡 Educational: Shareholders should note the new RTA contact details for future correspondence regarding share transfers, dematerialization, or dividend queries.

View All 526546 Announcements on Live Market Tracking →